Edmund Benami

Bugatone Ltd. engages in the development of a software to improve audio quality and measure biographical data while listening to music or talking on the phone. The company was founded by Noam Petrank and Edmund Ben Ami on February 14, 2013 and is headquartered in Tel Aviv, Israel.

Neuralight, Inc. was founded in 2021 by Edmund Benami and Micha Y. Breakstone, with Micha Y. Breakstone serving as the CEO since then. The Israeli company is focused on transforming clinical development, diagnostics, and precision medicine in neurology with AI. The company is developing an AI-driven platform to accelerate and improve drug development and patient monitoring, as well as introduce precision care for patients with neurological disorders using oculometric data captured with a standard webcam or smartphone.

Neuralight, Inc. was founded in 2021 by Edmund Benami and Micha Y. Breakstone, with Micha Y. Breakstone serving as the CEO since then. The Israeli company is focused on transforming clinical development, diagnostics, and precision medicine in neurology with AI. The company is developing an AI-driven platform to accelerate and improve drug development and patient monitoring, as well as introduce precision care for patients with neurological disorders using oculometric data captured with a standard webcam or smartphone.

Neuralight, Inc. was founded in 2021 by Edmund Benami and Micha Y. Breakstone, with Micha Y. Breakstone serving as the CEO since then. The Israeli company is focused on transforming clinical development, diagnostics, and precision medicine in neurology with AI. The company is developing an AI-driven platform to accelerate and improve drug development and patient monitoring, as well as introduce precision care for patients with neurological disorders using oculometric data captured with a standard webcam or smartphone.

Neuralight, Inc. was founded in 2021 by Edmund Benami and Micha Y. Breakstone, with Micha Y. Breakstone serving as the CEO since then. The Israeli company is focused on transforming clinical development, diagnostics, and precision medicine in neurology with AI. The company is developing an AI-driven platform to accelerate and improve drug development and patient monitoring, as well as introduce precision care for patients with neurological disorders using oculometric data captured with a standard webcam or smartphone.